SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Momenta Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (2721)1/25/2011 2:44:05 PM
From: tom pope  Read Replies (1) | Respond to of 3027
 
Seems to me that the question remaining is the length of time before approval of a TEVA drug - tho substitutability may yet be an issue, don't you think?



To: Biomaven who wrote (2721)1/25/2011 3:42:54 PM
From: IRWIN JAMES FRANKEL  Read Replies (1) | Respond to of 3027
 
>>Personally, I'd put the probability of a Teva approval at > 95% at this point. Likely take several months, so meantime MNTA will continue to rake in some cash.

So what do you place probability of TEVA launching if approved? (MNTA's claim of patent infringement)

ij


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News